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Epithelial-to-mesenchymal transition (EMT) is a cellular program that operates in the 
context of embryogenesis, wound-healing and carcinoma pathogenesis to drive epithelial 
cells toward a mesenchymal state. During carcinoma progression, EMT enables the cells 
forming these tumours to acquire the traits of highly malignant cells, notably motility, 
invasiveness and an ability to disseminate to form distant metastases. Indeed, a number of 
published reports have associated EMT with a variety of malignant carcinoma cells. 
Recently, however, Zheng et al. (1) reported that in genetically engineered mouse models of 
pancreatic adenocarcinoma development, carcinoma cells could metastasize without 
activating EMT programs. Their conclusions, if sustained by the evidence presented, would 
prompt a major change in how we conceptualize malignant progression and metastasis of 
carcinoma cells, including the neoplastic cells in human carcinomas.
To assess the role of EMT in metastasis, Zheng et al. deleted Snail or Twist – two important 
EMT-associated transcription factors (EMT-TFs). Despite this deletion, neither conditional 
knockout (CKO) exhibited a decrease in the rate of metastasis of pancreatic carcinoma cells. 
The authors concluded that EMT is dispensable for metastasis based on their claim that 
deletion of either Snail or Twist significantly attenuates EMT. However, evidence that EMT 
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programs were eliminated is lacking in their report, and thus this claim is not supported by 
their data.
It has been well-established that EMT is not a single, stereotypical program but instead has 
multiple manifestations, many of which endow epithelial cells – both normal and neoplastic 
– with a variety of traits normally expressed by mesenchymal cells (2, 3). Importantly, EMT 
is achieved through the action of multiple context-dependent signals and EMT-TFs; 
furthermore, cells activating an EMT program may lose their epithelial properties and 
acquire invasive properties by progressing only part way through an EMT program (“partial 
EMT”). These facts help to understand the EMT programs that likely persisted in the 
pancreatic carcinoma cells studied by Zheng et al.
To prove that EMT is indeed suppressed in the CKO tumours, Zheng et al. used a lineage 
traced mouse model of pancreatic cancer similar to the model previously reported by Rhim 
et al. (4), in which all carcinoma cells are unambiguously marked by the fluorescent protein 
YFP. They show that tumours in TwistcKO animals exhibited a significant reduction in the 
percentage of YFP+ cells that co-expressed the mesenchymal marker α-smooth muscle actin 
(αSMA) relative to tumours with an intact Twist locus. At face value, this would seem to be 
a good indicator that the EMT was indeed suppressed in the pancreatic carcinoma cells. 
However, unlike several other mesenchymal markers, αSMA expression is rarely induced 
upon activation of EMT in this mouse tumour model (Fig. 1).
Although the authors also stained for other EMT markers, including Zeb1, Zeb2, Slug, and 
Sox4, these stainings were done without marking the tumour cells with a lineage-specific 
tracer. Consequently, one cannot discern whether any particular detected staining was 
present in a carcinoma cell or in a non-neoplastic stromal cell that was recruited to a 
pancreatic tumour; for this reason, the impact on EMT of the Snail and the Twist deletion 
remains undefined. Indeed, there is abundant evidence that the tumours described in Zheng 
et al. continued to exhibit EMT phenotypes despite loss of either Snail or Twist. For 
example, poorly differentiated regions of these tumours – histologically defined zones 
reflecting EMT – were undiminished upon Snail or Twist deletion. Moreover, the tumour 
cells of the primary tumours still expressed considerable levels of the other EMT-TFs, as 
shown for the Zeb1, Sox4, and Slug EMT-TFs following deletion of either Snail or Twist.
Likewise, in carcinoma cells isolated from both of these primary CKO tumours, quantitative 
PCR demonstrated that expression of the Zeb1 and Slug mRNAs was reduced by ~2 fold, a 
decrease that is plausibly insignificant functionally; importantly, expression of the 
mesenchymal markers vimentin and N-cadherin was only slightly down-regulated and the 
down-regulation was statistically insignificant.
Thus, while the results of Zheng et al. are interesting and may speak to redundancy within 
the transcriptional network that defines and orchestrates EMT in pancreatic carcinomas, the 
authors nevertheless failed to achieve what they set out to do, namely to completely suppress 
activation of EMT. Hence, the conclusion that EMT is not required for metastatic 
dissemination cannot be sustained, simply because the authors’ genetic manipulations failed 
to suppress expression of versions of the EMT program. Accordingly, we continue to 
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embrace the notion that pancreatic carcinoma cells utilize an EMT program or programs 
during metastatic dissemination.
METHODS
Three well differentiated and three poorly differentiated tumours from LSL-Kras; p53fl/+; 
Pdxl-Cre; Rosa-YFP (KPCY) animals were embedded in paraffin following overnight 
fixation. Sections were stained with antibodies against GFP (Abcam ab6673) and either 
αSMA (Sigma F3777), Fsp1 (DAKO A5114), Vimentin (Cell Signaling D21H3), or Zeb1 
(Santa Cruz H102) using standard techniques. Images were obtained with an Olympus IX71 
fluorescent microscope and quantified using Fiji software. Staining for αSMA with Abcam 
ab5694 (as employed by Zheng et al.) gave similar results.
Acknowledgments
We thank Amine Sahmoud for assistance in preparing the figure.
References
1. Zheng X, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces 
chemoresistance in pancreatic cancer. Nature. 2015; 527:525–530. DOI: 10.1038/nature16064 
[PubMed: 26560028] 
2. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu 
Rev Cell Dev Biol. 2011; 27:347–376. DOI: 10.1146/annurev-cellbio-092910-154036 [PubMed: 
21740232] 
3. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science. 2013; 
342:1234850. [PubMed: 24202173] 
4. Rhim AD, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148:349–
361. DOI: 10.1016/j.cell.2011.11.025 [PubMed: 22265420] 
Aiello et al. Page 3
Nature. Author manuscript; available in PMC 2018 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Six pancreatic tumours from KPCY mice (4) were stained for YFP (tumour cells, red) and 
the mesenchymal markers Fsp1, vimentin (Vim), Zeb1, or αSMA (green). The analysis 
included three poorly differentiated tumors (with a high degree of EMT) and three well 
differentiated tumors (with a low degree of EMT) to reflect the heterogeneity seen in the 
KPCY model; all images were taken from the poorly differentiated tumors. Although there 
was wide variation in the frequency of Fsp1, Vimentin, and Zeb1 staining in the tumour 
cells, virtually all of the αSMA staining was confined to the non-tumour (YFP-negative) 
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stroma. This was true in both well-differentiated and poorly differentiated tumours (arrows 
indicate YFP+ tumour cells expressing the indicated marker; αSMA+YFP+ cells were 
extremely rare). These data were quantified in the graph below, demonstrating that αSMA 
expression is uncommon in the pancreatic carcinoma cells including those that have 
undergone an EMT. A minimum of 2,500 tumour cells were counted per mouse for each 
marker.
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